Farsoon Technologies plans up to 3.91 billion yuan private placement for AM platform and capacity expansion

Farsoon Technologies, the Changsha-based industrial 3D printing leader, announced on April 29 a private placement of up to 39.1 billion yuan (approximately $5.4 billion) to fund three core projects: an additive manufacturing integrated service platform (23.56 billion yuan), advanced AM equipment capacity expansion (10.75 billion yuan), and a global operations center network (4.78 billion yuan). The offering will be conducted via competitive book-building to no more than 35 qualified investors, with the issue price set at no less than 80% of the 20-day average trading price. The company, which develops both metal (SLM) and polymer (SLS) systems, materials, and software in-house, is targeting the shift from R&D-scale to serial production across medical, aerospace, and industrial verticals.

This capital raise is the largest single AM-sector equity financing in China's history and signals a structural escalation in the Chinese localization arc (Pattern P2). Farsoon is not merely matching Western LPBF and SLS specs; it is integrating materials development, service bureau capacity, and global support infrastructure into a single platform play. The 23.56 billion yuan service platform allocation — over 60% of total proceeds — is particularly notable, as it targets the full-chain bottleneck that has constrained Chinese AM adoption: fragmented post-processing, qualification support, and material certification. Farsoon's dual-technology position (metal + polymer) gives it a rare cross-process advantage, especially in medical-dental, where it has already enabled multiple NMPA Class III implant registrations through partners like Huaxiang Medical. The global operations center investment (4.78 billion yuan) directly addresses the geographic service gap that has limited Chinese AM exporters' ability to compete with EOS, SLM Solutions, and 3D Systems in regulated Western markets.

The practical test for Farsoon is execution, not ambition. Building a 23.56 billion yuan service platform requires not just capital but talent, regulatory expertise in multiple jurisdictions, and the ability to manage a hybrid hardware-service margin structure that few AM companies have sustained at scale. The medical vertical, where Farsoon has the deepest clinical references, will likely be the first to benefit, but aerospace qualification remains a multi-year grind even with expanded capacity. Investors should watch whether Farsoon can convert this capital into recurring service revenue and certified production contracts, or whether the platform investment becomes a cost center that dilutes its historically strong hardware margins.